Value-Based Insurance Plans Can Up Rx Adherence

Value-based insurance design (VBID) plans with certain features aside from solely lowering cost sharing can increase medication adherence, according to a study.
Published Online: March 07, 2014
Value-based insurance design (VBID) plans with certain features aside from solely lowering cost sharing can increase medication adherence, according to a study published in the March issue of Health Affairs.

Niteesh K. Choudhry, M.D., Ph.D., from Harvard University in Boston, and colleagues evaluated 76 VBID plans introduced by a large pharmacy benefit manager from 2007 to 2010.

The researchers found that VBID plans that made a significantly greater impact on adherence were more generous, targeted high-risk patients, offered wellness programs, did not offer disease management programs, and made the benefit available only for medication ordered by mail. The effects of these features were as large as four to five percentage points, compared to plans without these characteristics.

Read the full story here:http://bit.ly/1hPzT7v

Source: Doctor's Lounge



Feature
Recommended Articles
A study published in JAMA Oncology presents a new tool that can predict disease recurrence in oropharyngeal cancer patients.
Earnings calls over the past 2 days for Express Scripts and Sanofi offered starkly different views of pricing for the first PCSK9 inhibitor to reach the US market.
Clinical pathways (CPs) are increasingly being utilized to improve quality of care and control healthcare costs in the United States. A new report from Avalere Health examines the development of CPs, use of evidence to inform their design, implementation processes, and their impact on quality of care, costs, and outcomes.
The authors studied the usefulness of a regular telephone follow-up to improve adherence to oral antiosteoporosis treatments. Their results support such follow-up and the use of this strategy in routine clinical practice.
Picking the right measurements to assess improvement in medication management depends largely on the what group is being considered, said Woody Eisenberg, MD, senior vice president of performance measurement and strategic alliances for the Pharmacy Quality Alliance.